OTTAWA, Ontario — Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences company centered on developing and commercializing products for farm animals, accomplice animal and human purposes that safely enhances feed intake and helps immune function, thereby supporting usual successfully being and efficiency, publicizes that its Board of Administrators has permitted the issuance of 878,000 stock alternatives, including 685,000 alternatives granted to officers, directors and investor family personnel of the Corporation. The alternatives are exercisable up to 5 years from the issuing date and have a strike label of $0.20. These alternatives manufacture fragment of an complete remuneration equipment for directors, officers and workers of Avivagen.

About Avivagen

Avivagen is a life sciences company centered on developing and commercializing products for farm animals, accomplice animal and human purposes that, by safely supporting immune function, promote usual successfully being and efficiency. It’s a public company traded on the TSX Enterprise Alternate below the logo VIV and is headquartered in Ottawa, Canada, basically basically based in partnership facilities of the National Study Council of Canada. For added recordsdata, test with www.avivagen.com. The contents of the gain position are expressly not included by reference in this press release.

About OxC-beta™ Skills and OxC-beta™ Farm animals

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain vegatables and fruits their intellectual colours. Thru make stronger of immune function the technology offers a non-antibiotic technique of promoting successfully being and growth. OxC-beta™ Farm animals is a proprietary product confirmed to be an efficient and financial substitute to the antibiotics recurrently added to farm animals feeds. The product is for the time being on hand for sale in the United States, Philippines, Mexico, Taiwan, Original Zealand, Thailand, Brazil, Australia, and Malaysia.

Avivagen’s OxC-beta™ Farm animals product is protected, efficient and may perhaps well perhaps fulfill the international mandate to take all in-feed antibiotics as growth promoters. Somewhat about a international farm animals trials with poultry and swine utilizing OxC-beta™ Farm animals have confirmed that the product performs as well to, and, normally, in some aspects, better than in-feed antibiotics.

Ahead Trying Statements

This news release comprises certain forward-taking a gaze statements which may perhaps well be basically basically based upon the present expectations of administration. Ahead-taking a gaze statements dangle risks and uncertainties related to the industrial of Avivagen Inc. and the atmosphere whereby the industrial operates. Any statements contained herein which may perhaps well be not statements of historical info may perhaps well moreover very successfully be deemed to be forward-taking a gaze, including these known by the expressions “intention”, “stay wide awake for”, “seem”, “imagine”, “select into consideration”, “may perhaps well perhaps”, “estimate”, “query of”, “if”, “intend”, “function”, “hope”, “likely”, “may perhaps well moreover fair”, “thought”, “presumably”, “potentially”, “pursue”, “seem”, “should always”, “whether”, “will”, “would” and same expressions. Statements position out in this news release touching on to Avivagen’s expectations as to future growth and outcomes, the chance for OxC-beta™ Farm animals to interchange antibiotics in farm animals feeds as well to own a fundamental need for successfully being make stronger in certain farm animals purposes the assign antibiotics are precluded are all forward-taking a gaze statements. These forward-taking a gaze statements are self-discipline to a preference of risks and uncertainties that may perhaps well perhaps trigger right outcomes or events to fluctuate materially from present expectations. Avivagen’s products may perhaps well moreover fair not keep market acceptance or regulatory approval in contemporary jurisdictions or for new purposes and should always not be broadly licensed as a substitute for antibiotics in farm animals feeds, in each case due to many factors, quite about a which can moreover very successfully be out of doors of Avivagen’s build a watch on. Readers are referred to the threat factors related to the industrial of Avivagen position out in Avivagen’s most present administration’s discussion and prognosis of monetary condition on hand at www.SEDAR.com. Rather than as required by law, Avivagen assumes no duty to update the forward-taking a gaze statements, or to update the explanations why right outcomes may perhaps well perhaps fluctuate from these reflected in the forward-taking a gaze statements.

Neither TSX Enterprise Alternate nor its Law Companies and products Provider (as that term is defined in the insurance policies of the TSX Enterprise Alternate) accepts accountability for the adequacy or accuracy of this release.

Copyright © 2022 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

Peep supply version on businesswire.com: https://www.businesswire.com/news/home/20220620005475/en/

Contacts

Avivagen Inc.

Drew Basek

Director of Investor Relatives

100 Sussex Power, Ottawa, Ontario, Canada K1A 0R6

Phone: 416-540-0733

Email: d.basek@avivagen.com

Kym Anthony

Chief Executive Officer

100 Sussex Power, Ottawa, Ontario, Canada K1A 0R6

Head Command of job Phone: 613-949-8164

Web position: www.avivagen.com